Watanabe Hirofumi, Karayama Masato, Inoue Yusuke, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Fujisawa Tomoyuki, Enomoto Noriyuki, Nakamura Yutaro, Inui Naoki, Suda Takafumi
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.
Department of Chemotherapy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.
Respir Med Case Rep. 2022 Feb 18;36:101608. doi: 10.1016/j.rmcr.2022.101608. eCollection 2022.
A 72-year-old male patient with advanced lung adenocarcinoma harboring a mutation had received treatment with a BRAF inhibitor and a MEK inhibitor. Treatment was ceased after 40 days because of disease progression. Twenty-four days after treatment cessation, the man was referred to our hospital with worsening abdominal and back pain over 2 weeks. Computed tomography revealed a massive thrombus in the descending aorta, bilateral kidney infarction, splenic infarction, and intestinal enlargement due to ileus. He was diagnosed with multiple organ infarction caused by arterial thromboembolism. Tumors harboring mutations and BRAF/MEK inhibitor therapy both have the potential to increase thrombosis risk, and were therefore thought to be associated with the occurrence of aortic thrombosis.
一名72岁的晚期肺腺癌男性患者携带一种突变，曾接受BRAF抑制剂和MEK抑制剂治疗。40天后因疾病进展停止治疗。停药24天后，该男子因持续2周的腹部和背部疼痛加重被转诊至我院。计算机断层扫描显示降主动脉有巨大血栓、双侧肾梗死、脾梗死以及因肠梗阻导致的肠扩张。他被诊断为动脉血栓栓塞引起的多器官梗死。携带突变的肿瘤和BRAF/MEK抑制剂治疗都有可能增加血栓形成风险，因此被认为与主动脉血栓形成的发生有关。
